metricas
covid
Buscar en
Medicina Clínica
Toda la web
Inicio Medicina Clínica Outcome of tocilizumab treatment in corticosteroid-resistant thyroid eye disease
Journal Information
Vol. 160. Issue 3.
Pages 113-117 (February 2023)
Share
Share
Download PDF
More article options
Visits
4
Vol. 160. Issue 3.
Pages 113-117 (February 2023)
Brief report
Outcome of tocilizumab treatment in corticosteroid-resistant thyroid eye disease
Resultados del tratamiento con tocilizumab en la enfermedad ocular tiroidea resistente a glucocorticoides
Visits
4
Rubén Pampín-Sáncheza,
Corresponding author
pampin_3@hotmail.com

Corresponding author.
, Cristina Martínez-Mugica-Barbosaa, Eva María Fonseca-Aizpurub, Francisco Javier Barbazán-Vázqueza, Beatriz Fernández-Gonzáleza, Loreto Buznego-Súárezc
a Servicio de Farmacia, Hospital Universitario de Cabueñes, Gijón, Spain
b Servicio de Medicia Interna, Hospital Universitario de Cabueñes, Gijón, Spain
c Servicio de Oftalmología, Hospital Universitario de Cabueñes, Gijón, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (1)
Table 1. Baseline characteristics and secondary outcomes of study patients before and after treatment with intravenous Tocilizumab 8mg/kg.
Abstract
Introduction

Thyroid eye disease (TED) is a complex and incompletely understood rare autoimmune disorder.

Objectives

To analyze the experience and the outcomes obtained with the use of intravenous tocilizumab in the treatment of TED.

Methods

A retrospective analysis of adult patients diagnosed with active TED resistant to intravenous corticosteroids treated in a tertiary hospital between May 2012 and May 2021.

Results

Eleven patients were included with a mean age of 52±12 (range 35–67) years. Nine patients were female and two were male. Patients received a median of 5±3.2 doses. Twenty out of twenty-four eyes achieved inactivation of TED at week 16. Proptosis response was achieved in 6/8 patients and diplopia response in 3/8 patients. The GO-QOL questionnaire showed clinically significant improvement in 9/11 patients. No serious adverse effects were reported during tocilizumab treatment. One patient required decompressive surgery 15 months after tocilizumab therapy.

Conclusion

The results obtained show that the use of tocilizumab in the treatment of this pathology can be a good alternative.

Keywords:
Thyroid-stimulating antibodies
Corticosteroids
Gravesʹ ophthalmopathy
Interleukin 6
Tocilizumab
Resumen
Introducción

La orbitopatía tiroidea (OT) es una enfermedad rara autoinmune compleja que no se conoce completamente.

Objetivos

Analizar la experiencia y los resultados obtenidos con el uso de tocilizumab intravenoso en el tratamiento de la OT.

Métodos

Análisis retrospectivo de pacientes adultos diagnosticados de OT activa resistente a glucocorticoides por vía intravenosa tratados en un hospital terciario entre mayo del 2012 y mayo del 2021.

Resultados

Se incluyó a 11 pacientes con una edad media de 52±12 (rango 35 a 67) años. Nueve pacientes eran mujeres y 2, hombres. Los pacientes recibieron una mediana de 5±3,2 dosis. Veinte de 24 ojos lograron la inactivación de la OT en la semana 16. Se logró respuesta a la proptosis en 6/8 pacientes y respuesta a diplopía en 3/8 pacientes. El cuestionario GO-QoL mostró una mejora clínicamente significativa en 9/11 pacientes. No se notificaron efectos adversos graves durante el tratamiento con tocilizumab. Un paciente requirió cirugía descompresiva 15 meses después del tratamiento con tocilizumab.

Conclusiones

Los resultados obtenidos muestran que el uso de tocilizumab en el tratamiento de esta enfermedad puede ser una buena alternativa.

Palabras clave:
Anticuerpos antirreceptor de TSH
Glucocorticoides
Interlucina 6
Oftalmopatía de Graves
Tocilizumab

Article

These are the options to access the full texts of the publication Medicina Clínica
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.medcli.2020.07.031
No mostrar más